Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow derived mesenchymal stromal cells
- Development stage
- Phase 3
- Lead developer
- Corestemchemon
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal, Intradiscal, Intramyocardial, Intracoronary, Intraarticular, Local Injection
01
Overview
Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are a multipotent cell therapy product isolated from a patient's own bone marrow, expanded ex vivo, and re-administered to the same patient. These cells exhibit significant immunomodulatory and regenerative properties, acting through the secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), as well as through direct cell-to-cell interactions. BM-MSCs are being investigated for a wide range of conditions, including autoimmune diseases like rheumatoid arthritis and Crohn's disease, metabolic disorders such as type 2 diabetes, and degenerative conditions like amyotrophic lateral sclerosis (ALS) and osteoarthritis. The therapy aims to restore immune balance, reduce chronic inflammation, and promote tissue repair without the need for a specific molecular target.
- Brand names
- Neuronata-R
- Other names
- autologous BM-MSCsautologous bone marrow-derived mesenchymal stem cellsautologous BMSCsBM-MSCs
Beyond the preview
Go deeper on autologous bone marrow derived mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow derived mesenchymal stromal cells.